Group 1: Financial Performance - The company plans to distribute a cash dividend of RMB 8.00 per 10 shares, amounting to a total of RMB 5,347.77 million (including tax), which represents 194.02% of the net profit attributable to shareholders for the year 2023 [2][3][4]. - The net profit attributable to shareholders for 2023 was RMB 2,756.25 million, while the total distributable profit at the end of the reporting period was RMB 17,425.99 million [4][5]. - The cash dividend distribution will not affect the company's debt repayment ability or cause cash flow shortages [3][4]. Group 2: Strategic Adjustments - The company plans to adjust its sales personnel bonus incentive policy and implement measures to improve sales, including targeted training and strict management of daily operations [3][4]. - The company aims to optimize existing positions and improve per capita efficiency while controlling personnel increases to maintain healthy and stable operations [3][4]. Group 3: International Expansion - The company's overseas revenue for 2023 was RMB 5,921.09 million, reflecting a 4.86% increase compared to the same period in 2022 [3][4]. - The company intends to enhance its product development and sales capabilities in the U.S. and strengthen support for European partners to boost domestic product exports [3][4]. Group 4: Research and Development Focus - The company is focusing on developing a variety of analytical testing instruments and aims to expand its product offerings in this area to enhance market competitiveness [4][5]. - The company is investing in the development of new products, including full-spectrum inductively coupled plasma spectrometers and gas chromatography-mass spectrometry systems [4][5]. Group 5: Market Response and Policy Alignment - The company is closely monitoring government policies related to large-scale equipment updates and actively engaging with customers to meet their needs [5][6]. - The company has been enhancing its product levels and research capabilities to provide comprehensive solutions for experimental analysis and testing [5][6].
莱伯泰科(688056) - 2023年度暨2024年第一季度业绩说明会投资者关系活动记录表